Avalo Therapeutics annual gross profit
2015
2016
2017
2018
2020
2021
2022
2023
2024
2025
Avalo Therapeutics Gross Profit Growth & History (AVTX)
Avalo Therapeutics's gross profit was $59,000 for fiscal 2025.
View full Avalo Therapeutics company overviewAvalo Therapeutics annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $59,000 | −$748,000 | −92.69% |
| 2024 | 2024-12-31 | $807,000 | $167,000 | +26.09% |
| 2023 | 2023-12-31 | $640,000 | −$14.0M | −95.62% |
| 2022 | 2022-12-31 | $14.6M | $10.7M | +274.12% |
| 2021 | 2021-12-31 | $3.9M | −$2.5M | −38.94% |
| 2020 | 2020-12-31 | $6.4M | — | — |
| 2018 | 2018-12-31 | $3.8M | −$23.4M | −86.14% |
| 2017 | 2017-12-31 | $27.2M | $26.0M | +2257.14% |
| 2016 | 2016-12-31 | $1.2M | $1.2M | — |
| 2015 | 2015-12-31 | $0 | — | — |
Avalo Therapeutics quarterly gross profit
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $59,000 | −$46,000 | −43.81% |
| Q3 2025 | 2025-09-30 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $0 | $343,000 | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2024 | 2024-12-31 | $105,000 | −$687,000 | −86.74% |
| Q2 2024 | 2024-06-30 | −$343,000 | −$278,000 | — |
| Q4 2023 | 2023-12-31 | $792,000 | $515,000 | +185.92% |
| Q3 2023 | 2023-09-30 | −$11,000 | −$14.4M | — |
| Q2 2023 | 2023-06-30 | −$65,000 | $469,000 | — |
| Q1 2023 | 2023-03-31 | −$76,000 | −$529,000 | — |
| Q4 2022 | 2022-12-31 | $277,000 | $480,000 | — |
| Q3 2022 | 2022-09-30 | $14.4M | $14.0M | +3162.67% |
| Q2 2022 | 2022-06-30 | −$534,000 | −$3.8M | — |
| Q1 2022 | 2022-03-31 | $453,000 | $57,000 | +14.39% |
| Q4 2021 | 2021-12-31 | −$203,000 | −$1.6M | — |
| Q3 2021 | 2021-09-30 | $442,000 | −$592,000 | −57.25% |
| Q2 2021 | 2021-06-30 | $3.3M | $2.0M | +159.68% |
| Q1 2021 | 2021-03-31 | $396,000 | −$2.3M | −85.27% |
| Q4 2020 | 2020-12-31 | $1.4M | — | — |
| Q3 2020 | 2020-09-30 | $1.0M | −$1.0M | −50.02% |
| Q2 2020 | 2020-06-30 | $1.3M | $921,580 | +272.32% |
| Q1 2020 | 2020-03-31 | $2.7M | $864,179 | +47.38% |
| Q3 2019 | 2019-09-30 | $2.1M | $1.1M | +114.72% |
| Q2 2019 | 2019-06-30 | $338,420 | −$3.0M | −89.93% |
| Q1 2019 | 2019-03-31 | $1.8M | −$1.8M | −49.61% |
| Q4 2018 | 2018-12-31 | −$4.2M | −$3.8M | — |
| Q3 2018 | 2018-09-30 | $963,496 | −$24.1M | −96.15% |
| Q2 2018 | 2018-06-30 | $3.4M | $3.2M | +2030.66% |
| Q1 2018 | 2018-03-31 | $3.6M | $3.6M | +942387.24% |
| Q4 2017 | 2017-12-31 | −$358,000 | — | — |
| Q3 2017 | 2017-09-30 | $25.0M | — | — |
| Q2 2017 | 2017-06-30 | $157,800 | — | — |
| Q1 2017 | 2017-03-31 | $384 | — | — |
Avalo Therapeutics gross profit trends
Over the last five fiscal years, Avalo Therapeutics's gross profit decreased from $6.4M to $59,000, a change of −$6.3M. The latest reported quarter, Q4 2025, shows $59,000.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Avalo Therapeutics source filings ↗